Results 31 to 40 of about 66 (66)

Some aspects of the background symptomatic treatment of cognitive impairment of various severity types

open access: yesМедицинский совет, 2013
This literature review outlines the role of glutamatergic disturbances in the pathogenesis of cognitive disorders. There is data on the effectiveness of the glutamate NMDA-receptors antagonist - memantine - in patients with various dementias: Alzheimer's
I. S. Preobrazhenskaya
doaj   +1 more source

Some aspects of medication and non-medication treatment of Alzheimer's disease

open access: yesМедицинский совет, 2015
The article tells about a contemporary approach to the treatment of patients with Alzheimer's disease (AD). There are findings related to the effectiveness of the glutamate NMDA receptor antagonist memantine in AD, its effect on cognitive deficit ...
O. V. Kotova, E. S. Akarachkova
doaj   +1 more source

Pathogenesis, diagnosis and treatment of Alzheimer's disease

open access: yesМедицинский совет, 2015
The article is devoted to pathogenesis and diagnosis of Alzheimer's disease. The possibilities of treatment are discussed. Efficacy data for the basic symptomatic treatment of Alzheimer's disease, the potential and prospects of nootropic therapy are ...
A. A. Naumenko, I. S. Preobrazhenskaya
doaj   +1 more source

Bioequivalence study drug containing memantine

open access: yesФармакокинетика и Фармакодинамика, 2013
At present, Russia has developed domestic analogue of Memantine Akatinol — Memaneyrin in the form of droplets which is pharmaceutically equivalent drug memantine Akatinol.
A. A. Karlitskaya   +5 more
doaj  

ОЦЕНКА ЭФФЕКТИВНОСТИ ИСПОЛЬЗОВАНИЯ НЕЙРОПСИХОЛОГИЧЕСКИХ ШКАЛ В ДИАГНОСТИКЕ ПРЕДДЕМЕНТНЫХ И ДЕМЕНТНЫХ РАССТРОЙСТВ У ПАЦИЕНТОВ С БОЛЕЗНЬЮ АЛЬЦГЕЙМЕРА

open access: yesŽurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta
Введение. Деменция на сегодняшний день занимает седьмое место среди ведущих причин смертности в мире. Ведущая форма деменции в мировой практике – болезнь Альцгеймера (БА), на долю которой приходится примерно 60-70% случаев. Каждый год происходит почти 10
А. А. Лакутин   +3 more
doaj   +1 more source

Клинико-экономические аспекты терапии болезни Альцгеймера в России

open access: yesКачественная клиническая практика, 2018
Экселон ТТС обладает необходимыми клинико-экономическими характеристиками для включения в государственные программы лечения деменции. Он превосходит по показателю минимизации затрат Реминил (галантамин) и Акатинол (мемантина гидрохлорид), включенные в ...

doaj  

Modern approach in the therapy of Alzheimer's disease

open access: yesУчёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, 2014
Alzheimer's disease is a well-known neurodegenerative disorder. One of its main risk factors is age. Due to a worldwide increase of human longevity Alzheimer's disease became the most common form of dementia.
D. I. Rodin   +2 more
doaj   +1 more source

Cognitive impairment of neurodegenerative diseases

open access: yesМедицинский совет, 2013
The overview is based on modern Russian and global data on the prevalence, genetic and environmental risk factors, pathogenesis, disease pattern, diagnosis and treatment of neurodegenerative diseases with cognitive impairment.
V. V. Zakharov, N. V. Vakhnina
doaj   +1 more source

Accumulation of aggregated alpha-synuclein in neural tissue structures in neurodegenerative diseases

open access: yesActa Biomedica Scientifica
A critical analysis of the literature on the structure and properties of alpha-synuclein under physiological and pathological conditions is presented, when the conformation of this protein changes, which contributes to its aggregation and changes in ...
V. N. Salkov, D. N. Voronkov
doaj   +1 more source

Early diagnosis and treatment of Alzheimer's disease

open access: yesМедицинский совет, 2015
There is an overview of literature devoted to the early diagnosis and treatment of Alzheimer's disease (AD). Medication and non-medication treatment methods for AD are discussed.
V. A. Parfyonov
doaj   +1 more source

Home - About - Disclaimer - Privacy